Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib maintenance after bevacizumab in ovarian cancer
NCT04227522Phase 3Completed
- Sponsor
- NOGGO
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rucaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by NOGGO. Started Jun 2020; status: completed.
02
Drugs
rucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04227522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227522.